Berobenatide is an investigational ultra-long-acting GLP-1 peptide. In the 2026 VESPER-3 Phase 2b study, monthly maintenance produced up to 12.3% average placebo-adjusted weight loss at week 28.
What if a GLP-1 reminder moved from every week to just once a month? That is the simple reason berobenatide is getting attention. Its headline is not a new receptor. It is a much longer gap between planned injections.
Why berobenatide matters
It is testing whether one GLP-1 peptide can move from a weekly start to monthly maintenance.
What it is
An ultra-long-acting GLP-1 peptide.
Best monthly result
Up to 12.3% placebo-adjusted weight loss at week 28.
Current status
Investigational, with Phase 3 work beginning.
What is berobenatide?
Berobenatide is a GLP-1 receptor agonist peptide designed to stay active for an unusually long time. It was previously called PF’3944 and MET-097i.
GLP-1 is a signal involved in appetite and blood-sugar control. Medicines such as semaglutide use the same broad pathway, but that does not make the molecules identical. Berobenatide has its own structure, test methods and clinical plan.
The word “monthly” also needs one important detail: the Phase 2b study did not start with monthly injections on day one. Participants first received weekly treatment while the dose increased. Monthly maintenance came later.
What did the 2026 monthly study find?
The VESPER-3 Phase 2b trial enrolled about 270 adults with obesity or overweight. Participants received weekly treatment through week 12. The active groups then moved to one injection every four weeks through week 28.
At week 28, the strongest monthly-maintenance group reached up to 12.3% placebo-adjusted average weight loss under the efficacy analysis.
Here is the part that matters most:
| Question | Direct answer |
|---|---|
| Was maintenance monthly? | Yes, after 12 weeks of weekly treatment |
| How long was the full study period? | 28 weeks |
| Best reported monthly result | Up to 12.3% placebo-adjusted average weight loss |
| Does this prove long-term monthly use? | No; Phase 3 must confirm it |
This is a strong proof-of-concept result. It is not a head-to-head win over weekly semaglutide, tirzepatide or another monthly program because those studies used different people, timelines and statistical plans.
Why are 12.3% and 15.9% both in berobenatide news?
They come from different VESPER studies.
- 12.3% was the best placebo-adjusted result reported for the monthly maintenance study, VESPER-3, at week 28.
- 15.9% was the average change from starting weight in an extension of VESPER-1 at week 32 using weekly 2.4 mg treatment.
The 15.9% number should not be used as the monthly result. Keeping those studies separate makes the article more useful and more trustworthy.
How does berobenatide compare with MariTide?
Both programs are part of the race to make GLP-1 treatment less frequent. Their designs are very different.
| Berobenatide | MariTide | |
|---|---|---|
| Main design | Ultra-long-acting peptide | Peptide-antibody conjugate |
| Main receptor plan | Activates GLP-1 | Activates GLP-1 and blocks GIP |
| Headline schedule | Monthly maintenance | Monthly treatment |
| Current evidence | Phase 2b; Phase 3 beginning | Phase 2; Phase 3 underway |
Think of them as two engineering answers to the same consumer question: Can a long-term GLP-1 plan require fewer reminders?
Read our MariTide 2026 guide for its separate Phase 2 results and monthly design. For the established weekly pathway, start with what is semaglutide?.
Did berobenatide also show a blood-sugar result?
Yes. VESPER-2 studied adults with type 2 diabetes. At week 28, Pfizer reported an average 2.2 percentage-point HbA1c reduction with weekly 1.6 mg under the efficacy analysis, compared with 0.2 points for placebo.
HbA1c is a blood test that reflects average blood sugar over the previous few months. This result came from a weekly study, not the monthly-maintenance study. That distinction matters when comparing headlines.
What side effects were reported?
Pfizer described the Phase 2b program as having favorable tolerability, with mostly gastrointestinal events such as nausea. The company also reported low rates of treatment discontinuation.
That is encouraging, but it is still company-reported Phase 2b evidence. Larger Phase 3 trials are designed to give a clearer picture across more people and a longer period.
What happens next?
Pfizer says the VESPER-6 Phase 3 monthly study is open for enrollment. That study should answer the questions that matter commercially:
- Can the monthly result hold up in a larger population?
- How many people stay on the planned schedule?
- Does the effect remain steady between monthly injections?
- What starting and step-up plan is most practical?
- Can the product be manufactured consistently at commercial scale?
Convenience is more than a marketing line. A monthly product could reduce the number of planned injections from about 52 a year to about 12. That may make adherence and travel easier if later trials confirm the benefit and safety.
Why long action changes the research specification
An ultra-long-acting peptide should never be purchased as a generic “monthly GLP-1.” Long action can depend on precise molecular design, formulation and stability.
Research buyers should request:
- the exact compound name, molecular form and identifier;
- HPLC purity plus mass-spectrometry identity;
- assay or peptide content when the project requires it;
- stability and aggregation information relevant to the intended work;
- storage and shipping conditions; and
- a current COA tied to the actual batch.
Use our peptide quality testing guide to match each claim with the right test. The COA vs specification sheet guide explains why a target limit and an actual batch result are not the same document.
The bottom line
Berobenatide’s direct answer is: up to 12.3% placebo-adjusted average weight loss at week 28 after a weekly start and monthly maintenance in Phase 2b. That makes it a serious 2026 entry in the move from weekly to monthly GLP-1s.
It remains investigational. For current laboratory work, compare available GLP-1 research peptides by exact identity, batch testing, format and documentation—not by a broad receptor label alone.
Review current semaglutide research specifications →
Sources and further reading
- Pfizer: VESPER Phase 2b berobenatide results
- Pfizer: VESPER-3 monthly-maintenance study details
- ClinicalTrials.gov: VESPER-3 study NCT06973720
This article explains public research reported through August 8, 2026. Berobenatide is investigational and is not offered here as a medicine or for personal use.
Frequently asked questions
What is berobenatide?
Berobenatide is an investigational ultra-long-acting GLP-1 receptor agonist peptide. It is being studied with a weekly start followed by once-monthly maintenance injections.
How much weight loss did monthly berobenatide produce?
In the 2026 VESPER-3 Phase 2b trial, the strongest monthly-maintenance group produced up to 12.3% average placebo-adjusted weight loss at week 28 under the efficacy analysis.
Is berobenatide taken weekly or monthly?
Both schedules have been studied. VESPER-3 used weekly treatment through week 12 and then monthly maintenance through week 28, while VESPER-1 studied weekly dosing for longer.
Is berobenatide the same as semaglutide or MariTide?
No. All three act on GLP-1 pathways, but berobenatide, semaglutide and MariTide are different molecules with different designs, schedules and clinical programs.
Is berobenatide approved?
No. Berobenatide remains investigational. Phase 2b findings support Phase 3 study but do not make it an approved medicine or a product for personal use.
What should research buyers verify for an ultra-long-acting peptide?
Verify exact molecular identity, form, assay, HPLC purity, mass-spectrometry identity, stability data, storage requirements and a current batch-specific COA.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →